{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:40:51Z","timestamp":1785552051682,"version":"3.56.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"am","delay-in-days":326,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000069","name":"NIAMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.det.2024.02.008","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T13:31:26Z","timestamp":1708954286000},"page":"417-428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Using Guidelines of Care to Lower Cardiovascular Risk in Patients with Psoriasis"],"prefix":"10.1016","volume":"42","author":[{"given":"William B.","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Soffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Gelfand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.det.2024.02.008_bib1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis Prevalence in Adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.008_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A\u00a0systematic review of worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.det.2024.02.008_bib3","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jaad.2008.09.022","article-title":"The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004","volume":"60","author":"Kurd","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.008_bib4","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities","volume":"80","author":"Elmets","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"25","key":"10.1016\/j.det.2024.02.008_bib5","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"Supplement","key":"10.1016\/j.det.2024.02.008_bib6","doi-asserted-by":"crossref","first-page":"S05","DOI":"10.21101\/cejph.a6806","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"30","author":"Kampe","year":"2022","journal-title":"Cent Eur J Public Health"},{"issue":"5","key":"10.1016\/j.det.2024.02.008_bib7","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","article-title":"Prevalence of cardiovascular risk factors in patients with psoriasis","volume":"55","author":"Neimann","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.008_bib8","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaad.2012.08.015","article-title":"Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies","volume":"68","author":"Armstrong","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"14","key":"10.1016\/j.det.2024.02.008_bib9","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of myocardial infarction in patients with psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.det.2024.02.008_bib10","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1038\/jid.2009.112","article-title":"The risk of stroke in patients with psoriasis","volume":"129","author":"Gelfand","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.02.008_bib11","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/archderm.143.12.1493","article-title":"The risk of mortality in patients with psoriasis: results from a population-based study","volume":"143","author":"Gelfand","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2024.02.008_bib12","article-title":"Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study","author":"Dubreuil","year":"2013","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.det.2024.02.008_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002739","article-title":"Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study","volume":"16","author":"Budu-Aggrey","year":"2019","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.det.2024.02.008_bib14","first-page":"S82","article-title":"Psoriasis is associated with an increased prevalence of metabolic syndrome that varies directly with objectively measured severity","volume":"131","author":"Langan","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.008_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaad.2017.10.050","article-title":"Psoriasis and the risk of diabetes: A prospective population-based cohort study","volume":"78","author":"Wan","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.02.008_bib16","article-title":"Psoriasis Increased the Risk of Adverse Cardiovascular Outcomes: A New Systematic Review and Meta-Analysis of Cohort Study","volume":"9","author":"Liu","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.det.2024.02.008_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jid.2017.07.841","article-title":"Objective Measures of Psoriasis Severity Predict Mortality: A Prospective Population-Based Cohort Study","volume":"138","author":"Noe","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.008_bib18","article-title":"Diabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of Adults","volume":"8","author":"Raghavan","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.det.2024.02.008_bib19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.det.2024.02.008_bib20","doi-asserted-by":"crossref","first-page":"775 e1-e6","DOI":"10.1016\/j.amjmed.2011.03.028","article-title":"Attributable risk estimate of severe psoriasis on major cardiovascular events","volume":"124","author":"Mehta","year":"2011","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.det.2024.02.008_bib21","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1038\/s41467-022-34323-4","article-title":"Shared genetic risk factors and causal association between psoriasis and coronary artery disease","volume":"13","author":"Patrick","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.det.2024.02.008_bib22","article-title":"The relationship between blood lipid and risk of psoriasis: univariable and multivariable Mendelian randomization analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.det.2024.02.008_bib23","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/jdv.12768","article-title":"Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort","volume":"29","author":"Ahlehoff","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.det.2024.02.008_bib24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaad.2013.09.020","article-title":"From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies","volume":"70","author":"Hugh","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.008_bib25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jaad.2004.06.017","article-title":"Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis","volume":"52","author":"Prodanovich","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.det.2024.02.008_bib26","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/archdermatol.2012.2502","article-title":"Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis","volume":"148","author":"Wu","year":"2012","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.008_bib27","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaad.2019.04.055","article-title":"Lack of association of biologic therapy for psoriasis with psychiatric illness: An electronic medical records cohort study","volume":"81","author":"Margolis","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.02.008_bib28","article-title":"Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis","author":"Mattay","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.det.2024.02.008_bib29","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jamacardio.2019.2589","article-title":"Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index","volume":"4","author":"Elnabawi","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"4","key":"10.1016\/j.det.2024.02.008_bib30","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/cvr\/cvz009","article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study","volume":"115","author":"Elnabawi","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.det.2024.02.008_bib31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","article-title":"A\u00a0Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.02.008_bib32","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1001\/jamadermatol.2022.3862","article-title":"Association of Apremilast With Vascular Inflammation and\u00a0Cardiometabolic Function in Patients With Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial","volume":"158","author":"Gelfand","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.det.2024.02.008_bib33","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1016\/j.jid.2021.03.024","article-title":"Impact of Biological Agents on Imaging and Biomarkers of Cardiovascular Disease in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials","volume":"141","author":"Gonz\u00e1lez-Cantero","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.008_bib34","article-title":"Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990-2011","volume":"6","author":"Bikdeli","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.det.2024.02.008_bib35","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-Dose Methotrexate for the Prevention of Atherosclerotic Events","volume":"380","author":"Ridker","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.det.2024.02.008_bib36","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.det.2024.02.008_bib37","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"7855","key":"10.1016\/j.det.2024.02.008_bib38","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.det.2024.02.008_bib39","article-title":"Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention","volume":"10","author":"Vaidya","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.det.2024.02.008_bib40","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41467-019-13756-4","article-title":"Neutrophil extracellular trap-associated RNA and LL37 enable self-amplifying inflammation in psoriasis","volume":"11","author":"Herster","year":"2020","journal-title":"Nat Commun"},{"issue":"19","key":"10.1016\/j.det.2024.02.008_bib41","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in Patients with Chronic Coronary Disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.det.2024.02.008_bib42","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.det.2024.02.008_bib43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaad.2018.03.046","article-title":"Commentary: Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality?: A critical question that we are only just beginning to answer","volume":"79","author":"Gelfand","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.02.008_bib44","doi-asserted-by":"crossref","first-page":"h1551","DOI":"10.1136\/bmj.h1551","article-title":"Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium","volume":"350","author":"Mons","year":"2015","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.det.2024.02.008_bib45","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2018.07.008","article-title":"Prevention and Control of Hypertension: JACC Health Promotion Series","volume":"72","author":"Carey","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.det.2024.02.008_bib46","article-title":"Effect of Statins on All-Cause Mortality in Adults: A Systematic Review and Meta-Analysis of Propensity Score-Matched Studies","volume":"11","author":"Nowak","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"8","key":"10.1016\/j.det.2024.02.008_bib47","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40261-017-0533-0","article-title":"Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis","volume":"37","author":"Ports","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.det.2024.02.008_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2019.90343","article-title":"The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials","volume":"16","author":"Socha","year":"2020","journal-title":"Arch Med Sci"},{"issue":"1","key":"10.1016\/j.det.2024.02.008_bib49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3899\/jrheum.210006","article-title":"Risk Factors for Diagnosis of Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis, and Ankylosing Spondylitis: A Set of Parallel Case-control Studies","volume":"49","author":"Meer","year":"2022","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.det.2024.02.008_bib50","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.jid.2022.02.020","article-title":"Is It Prime Time for Statin Therapy in Psoriasis?","volume":"142","author":"Mehta","year":"2022","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.008_bib51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clindermatol.2017.09.005","article-title":"Psoriasis and the metabolic syndrome","volume":"36","author":"Gisondi","year":"2018","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.det.2024.02.008_bib52","doi-asserted-by":"crossref","first-page":"f5961","DOI":"10.1136\/bmj.f5961","article-title":"Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. Research Support, N.I.H., Extramural","volume":"347","author":"Wan","year":"2013","journal-title":"Bmj"},{"issue":"4","key":"10.1016\/j.det.2024.02.008_bib53","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jaad.2017.06.028","article-title":"The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events","volume":"77","author":"Egeberg","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.008_bib54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7326\/M17-3011","article-title":"Clinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic Cardiovascular Disease Risk","volume":"169","author":"Yadlowsky","year":"2018","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.det.2024.02.008_bib55","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.jid.2023.03.1655","article-title":"Regional Variation in Cardiovascular Risk Factor Screening by Dermatologists for Psoriasis Patients in the United States","volume":"143","author":"Song","year":"2023","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.008_bib56","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bjd.14557","article-title":"Primary care-based screening for cardiovascular risk factors in patients with psoriasis","volume":"175","author":"Rutter","year":"2016","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.02.008_bib57","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2011.06.035","article-title":"Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis","volume":"67","author":"Kimball","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.02.008_bib58","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3899\/jrheum.170379","article-title":"Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study","volume":"45","author":"Eder","year":"2018","journal-title":"J\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.det.2024.02.008_bib59","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1001\/jamadermatol.2014.2094","article-title":"Effect of psoriasis severity on hypertension control: a population-based study in the United Kingdom","volume":"151","author":"Takeshita","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2024.02.008_bib60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jdin.2020.10.010","article-title":"Use of primary care services among patients with chronic skin disease seen by dermatologists","volume":"2","author":"Barbieri","year":"2021","journal-title":"JAAD Int"},{"issue":"3","key":"10.1016\/j.det.2024.02.008_bib61","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jamadermatol.2021.4467","article-title":"Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease","volume":"158","author":"Barbieri","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.02.008_bib62","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/24755303221101848","article-title":"Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons Living With Psoriatic Disease","volume":"7","author":"Gustafson","year":"2022","journal-title":"J\u00a0Psoriasis Psoriatic Arthritis"},{"issue":"5S","key":"10.1016\/j.det.2024.02.008_bib63","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/j.jid.2023.03.676","article-title":"Prevention of cardiovascular disease and mortality in patients with psoriasis or psoriatic arthritis (CP3) study: Preliminary results. Abstract","volume":"153","author":"Neopaney","year":"2023","journal-title":"J\u00a0Invest Dermatol"},{"issue":"23","key":"10.1016\/j.det.2024.02.008_bib64","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1161\/CIR.0000000000001031","article-title":"2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association","volume":"144","author":"Lichtenstein","year":"2021","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.det.2024.02.008_bib65","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005263","article-title":"Physical Activity Guidelines for Americans From the US Department of Health and Human Services","volume":"11","author":"Piercy","year":"2018","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524000202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T21:39:24Z","timestamp":1716500364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524000202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0733863524000202"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.02.008","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using Guidelines of Care to Lower Cardiovascular Risk in Patients with Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}